Tohoku University School of Medicine, Sendai, Miyagi, Japan.
Higashi Totsuka Memorial Hospital, Yokohama, Kanagawa, Japan.
BMC Med Ethics. 2024 Oct 29;25(1):121. doi: 10.1186/s12910-024-01126-9.
Financial relationships between clinical guideline authors and pharmaceutical companies introduce conflicts of interest (COI), potentially biasing guideline recommendations. Thus, proper management of COI is paramount for clinical guideline authors. Nevertheless, little is known about COI among neurology clinical guideline authors. This study aimed to evaluate the financial relationships between pharmaceutical companies and authors of Clinical Practice Guideline for Headache Disorders (CPGHD) in Japan.
This is a retrospective analysis of 2016-2020 personal payments data disclosed by all pharmaceutical companies affiliated with the Japan Pharmaceutical Manufacturers Association. We examined amounts and fraction of personal payments to all 57 CPGHD authors and all neurologists board-certified by the Japanese Society of Neurology. Payment data was descriptively analyzed at individual author level.
Among 57 CPGHD authors, 56 (98.3%) received personal payments totaling $2.7 million from pharmaceutical companies between 2016 and 2020. Median five-year payments were $89,955 for CPGHD authors, while $521 for board-certified neurologists. The CPGHD chairperson and vice chairperson received substantial payments during the guideline development period. Nevertheless, because of less rigorous and transparent COI policy compared to international standard policies, only 10 authors disclosed their financial relationships with the pharmaceutical companies in the guideline.
More than 98% of CPGHD authors received much higher personal payments from pharmaceutical companies than those to board-certified neurologists during the guideline development period in Japan.
临床指南作者与制药公司之间的财务关系会引发利益冲突（COI），从而可能使指南推荐产生偏差。因此，妥善管理 COI 对于临床指南作者至关重要。然而，人们对神经科临床指南作者的 COI 知之甚少。本研究旨在评估日本头痛疾病临床实践指南（CPGHD）作者与制药公司之间的财务关系。
这是对日本制药商协会附属的所有制药公司在 2016 年至 2020 年期间披露的个人支付数据进行的回顾性分析。我们检查了 57 位 CPGHD 作者和所有通过日本神经病学会认证的神经病学家的个人支付金额和个人支付比例。按作者个人进行支付数据的描述性分析。
在 57 位 CPGHD 作者中，有 56 位（98.3%）在 2016 年至 2020 年期间从制药公司收到了总计 270 万美元的个人报酬。CPGHD 作者五年的中位数支付额为 89955 美元，而认证神经病学家为 521 美元。指南制定期间，CPGHD 主席和副主席收到了大量的报酬。尽管与国际标准政策相比，COI 政策不够严格和透明，但只有 10 位作者在指南中披露了他们与制药公司的财务关系。
在日本，超过 98%的 CPGHD 作者在指南制定期间从制药公司获得的个人报酬远高于认证神经病学家。
